Potential of telomerase-specific oncolytic adenovirus as an immunogenic drug producing synergy with anti-PD-1 therapy

被引：0

作者：

Kanaya, Nobuhiko ^{[1
]}

Kuroda, Shinji ^{[1
]}

Morihiro, Toshiaki ^{[1
]}

Kubota, Tetsushi ^{[1
]}

Tazawa, Hiroshi ^{[1
]}

Kikuchi, Satoru ^{[1
]}

Nishizaki, Masahiko ^{[1
]}

Kagawa, Shunsuke ^{[1
]}

Urata, Yasuo ^{[2
]}

Fujiwara, Toshiyoshi ^{[1
]}

机构：

[1] Okayama Univ, Dept Grastroenterol Surg, Okayama, Japan

[2] Oncolys BioPharma Inc, Tokyo, Japan

来源：

CANCER SCIENCE | 2018年 / 109卷

关键词：

Oncolytic virus; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-3178

引用

页码：1059 / 1059

页数：1

共 50 条

[21] Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Goldinger, Simone M.
Stieger, Pascale
Meier, Barbara
Micaletto, Sara
Contassot, Emmanuel
French, Lars E.
Dummer, Reinhard
CLINICAL CANCER RESEARCH, 2016, 22 (16) : 4023 - 4029
[22] Lichen planus-like drug eruption on anti-PD-1 therapy
Kratzsch, Dorothea
Simon, Jan-Christoph
Ziemer, Mirjana
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 (12): : 1238 - 1240
[23] CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
Li, Xiaofei
Lu, Mingjie
Yuan, Manman
Ye, Jing
Zhang, Wei
Xu, Lingyan
Wu, Xiaohan
Hui, Bingqing
Yang, Yuchen
Wei, Bin
Guo, Ciliang
Wei, Min
Dong, Jie
Wu, Xingxin
Gu, Yanhong
ONCOIMMUNOLOGY, 2022, 11 (01):
[24] Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy
Cao, Yiyi
Li, Wenbo
Wang, ZhengJie
Pang, Hua
TUMORI JOURNAL, 2021, 107 (04): : 282 - 291
[25] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
Yamaguchi, Hirohito
Wang, Shao-Chun
Hung, Mien-Chie
CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
[26] Telomerase-specific oncolytic adenovirus mediates molecular sensitization to ionizing radiation in human cancer cells through E1B55kDa expression
Kuroda, Shinji
Fujiwara, Toshiya
Tazawa, Hiroshi
Uno, Futoshi
Kagawa, Shunsuke
Hashimoto, Yuuri
Ouchi, Masaaki
Urata, Yasuo
Tanaka, Noriaki
Fujiwara, Toshiyoshi
CANCER RESEARCH, 2009, 69
[27] Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice
Zhou, Heng
Tu, Chen
Yang, Pengfei
Li, Jin
Kepp, Oliver
Li, Haining
Zhang, Liying
Zhang, Lixin
Zhao, Yang
Zhang, Tianyi
Sheng, Chengyan
Wang, Jufang
ONCOIMMUNOLOGY, 2022, 11 (01):
[28] Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E.
Menzies, A. M.
Kong, B. Y.
Cooper, A.
Ramanujam, S.
Lo, S.
Kefford, R. F.
Fogarty, G. B.
Guminski, A.
Wang, T. W.
Carlino, M. S.
Hong, A.
Long, G. V.
ONCOIMMUNOLOGY, 2016, 5 (09):
[29] An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy
Yang, Yuefeng
Xu, Weidong
Peng, Di
Wang, Hao
Zhang, Xiaoyan
Wang, Hua
Xiao, Fengjun
Zhu, Yitan
Ji, Yuan
Gulukota, Kamalakar
Helseth, Donald L., Jr.
Mangold, Kathy A.
Sullivan, Megan
Kaul, Karen
Wang, Edward
Prabhakar, Bellur S.
Li, Jinnan
Wu, Xuejie
Wang, Lisheng
Seth, Prem
HUMAN GENE THERAPY, 2019, 30 (09) : 1117 - 1132
[30] Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy
Hou, Chongxian
Shi, Shenbao
Gao, Mengjiao
Ji, Jingsen
Ma, Chengcheng
Wang, Tianwei
Chen, Taoliang
Liu, Yang
Zhong, Jiasheng
Zheng, Yaofeng
Ye, Jing'an
Ke, Yiquan
JOURNAL OF NEURO-ONCOLOGY, 2023, 165 (01) : 79 - 90

← 1 2 3 4 5 →